BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Asai H, Hirano M, Furiya Y, Udaka F, Morikawa M, Kanbayashi T, Shimizu T, Ueno S. Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease. Clinical Neurology and Neurosurgery 2009;111:341-4. [DOI: 10.1016/j.clineuro.2008.11.007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Liu M, Jiao Q, Du X, Bi M, Chen X, Jiang H. Potential Crosstalk Between Parkinson's Disease and Energy Metabolism. Aging Dis 2021;12:2003-15. [PMID: 34881082 DOI: 10.14336/AD.2021.0422] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Tabikh M, Chahla C, Okdeh N, Kovacic H, Sabatier J, Fajloun Z. Parkinson disease: protective role and function of neuropeptides. Peptides 2021. [DOI: 10.1016/j.peptides.2021.170713] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Adam O, Azher S, Valachovic E, Hahn A, Molho E. Narcolepsy genetic marker HLA DQB1*06:02 and excessive daytime sleepiness in Parkinson disease patients treated with dopaminergic agents. J Neurol 2021. [PMID: 34559298 DOI: 10.1007/s00415-021-10813-1] [Reference Citation Analysis]
4 Wang Q, Cao F, Wu Y. Orexinergic System in Neurodegenerative Diseases. Front Aging Neurosci 2021;13:713201. [PMID: 34483883 DOI: 10.3389/fnagi.2021.713201] [Reference Citation Analysis]
5 Al-Kuraishy HM, Abdulhadi MH, Hussien NR, Al-Niemi MS, Rasheed HA, Al-Gareeb AI. Involvement of orexinergic system in psychiatric and neurodegenerative disorders: A scoping review. Brain Circ 2020;6:70-80. [PMID: 33033776 DOI: 10.4103/bc.bc_42_19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
6 Liu C, Xue Y, Liu MF, Wang Y, Chen L. Orexin and Parkinson's disease: A protective neuropeptide with therapeutic potential. Neurochem Int 2020;138:104754. [PMID: 32422324 DOI: 10.1016/j.neuint.2020.104754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Berhe DF, Gebre AK, Assefa BT. Orexins role in neurodegenerative diseases: From pathogenesis to treatment. Pharmacol Biochem Behav 2020;194:172929. [PMID: 32315694 DOI: 10.1016/j.pbb.2020.172929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
8 Antelmi E, Pizza F, Franceschini C, Ferri R, Plazzi G. REM sleep behavior disorder in narcolepsy: A secondary form or an intrinsic feature? Sleep Med Rev 2020;50:101254. [PMID: 31931470 DOI: 10.1016/j.smrv.2019.101254] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
9 Stanojlovic M, Pallais JP, Kotz CM. Chemogenetic Modulation of Orexin Neurons Reverses Changes in Anxiety and Locomotor Activity in the A53T Mouse Model of Parkinson's Disease. Front Neurosci 2019;13:702. [PMID: 31417337 DOI: 10.3389/fnins.2019.00702] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Stanojlovic M, Pallais Yllescas JP Jr, Vijayakumar A, Kotz C. Early Sociability and Social Memory Impairment in the A53T Mouse Model of Parkinson's Disease Are Ameliorated by Chemogenetic Modulation of Orexin Neuron Activity. Mol Neurobiol 2019;56:8435-50. [PMID: 31250383 DOI: 10.1007/s12035-019-01682-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
11 Ono H, Kanbayashi T, Imanishi A, Ayabe T, Sagawa Y, Tsutsui K, Ohmori Y, Takeshima M, Nishino S, Shimizu T. Clinical characteristics of symptomatic narcolepsy or hypersomnia: an analysis of 182 consecutive cases with neurological disorders associated with hypersomnolence. Sleep Biol Rhythms 2019;17:123-40. [DOI: 10.1007/s41105-018-0186-2] [Reference Citation Analysis]
12 Wilson H, Giordano B, Turkheimer FE, Chaudhuri KR, Politis M. Serotonergic dysregulation is linked to sleep problems in Parkinson's disease. Neuroimage Clin 2018;18:630-7. [PMID: 29845011 DOI: 10.1016/j.nicl.2018.03.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
13 Khoo SY, McNally GP, Clemens KJ. The dual orexin receptor antagonist TCS1102 does not affect reinstatement of nicotine-seeking. PLoS One 2017;12:e0173967. [PMID: 28296947 DOI: 10.1371/journal.pone.0173967] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
14 Porter VR, Buxton WG, Avidan AY. Sleep, Cognition and Dementia. Curr Psychiatry Rep 2015;17:97. [PMID: 26478197 DOI: 10.1007/s11920-015-0631-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 6.7] [Reference Citation Analysis]
15 Malkani R, Attarian H. Sleep in Neurodegenerative Disorders. Curr Sleep Medicine Rep 2015;1:81-90. [DOI: 10.1007/s40675-015-0016-x] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
16 Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Agúndez JA. Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease. Front Cell Neurosci 2014;8:369. [PMID: 25426023 DOI: 10.3389/fncel.2014.00369] [Cited by in Crossref: 13] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
17 Yeung EYH, Cavanna AE. Sleep Attacks in Patients With Parkinson's Disease on Dopaminergic Medications: A Systematic Review. Mov Disord Clin Pract 2014;1:307-16. [PMID: 30363881 DOI: 10.1002/mdc3.12063] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
18 Távora DG, de Bruin VM, Lopes Gama R, Lopes EM, Jorge IF, de Bruin PF. The nature of excessive sleepiness and sudden sleep onset in Parkinson׳s disease. Sleep Sci 2014;7:13-8. [PMID: 26483896 DOI: 10.1016/j.slsci.2014.07.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
19 Chen Q, de Lecea L, Hu Z, Gao D. The hypocretin/orexin system: an increasingly important role in neuropsychiatry. Med Res Rev 2015;35:152-97. [PMID: 25044006 DOI: 10.1002/med.21326] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
20 Malhotra R, Avidan AY. Neurodegenerative Disease and REM Behavior Disorder. Curr Treat Options Neurol 2012;14:474-92. [PMID: 22879077 DOI: 10.1007/s11940-012-0194-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
21 Ferrer I, López-Gonzalez I, Carmona M, Dalfó E, Pujol A, Martínez A. Neurochemistry and the non-motor aspects of PD. Neurobiol Dis 2012;46:508-26. [PMID: 22737710 DOI: 10.1016/j.nbd.2011.10.019] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 5.9] [Reference Citation Analysis]
22 Drouot X, Moutereau S, Lefaucheur JP, Palfi S, Covali-Noroc A, Margarit L, Stoïca-Herman M, Nguyen JP, Césaro P, d'Ortho MP. Low level of ventricular CSF orexin-A is not associated with objective sleepiness in PD. Sleep Med 2011;12:936-7. [PMID: 21978722 DOI: 10.1016/j.sleep.2011.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
23 Mehanna R, Ondo WG. Sleep problems in Parkinson’s disease patients. Neurodegenerative Disease Management 2011;1:307-21. [DOI: 10.2217/nmt.11.33] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
24 Cui LB, Li BW, Jin XH, Zhao L, Shi J. Progressive changes of orexin system in a rat model of 6-hydroxydopamine-induced Parkinson's disease. Neurosci Bull 2010;26:381-7. [PMID: 20882064 DOI: 10.1007/s12264-010-0410-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
25 Wakai M, Kanbayashi T. Narcolepsy due to Parkinson's disease with a decrease in cerebrospinal-fluid orexin: a case report: Narcolepsy due to PD with low orexin. Sleep and Biological Rhythms 2011;9:127-9. [DOI: 10.1111/j.1479-8425.2011.00489.x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
26 Ferrer I. Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease. Parkinsons Dis 2011;2011:708404. [PMID: 21403906 DOI: 10.4061/2011/708404] [Cited by in Crossref: 16] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
27 Mukaetova-Ladinska EB, Monteith R, Perry EK. Cerebrospinal fluid biomarkers for dementia with lewy bodies. Int J Alzheimers Dis 2010;2010:536538. [PMID: 21048932 DOI: 10.4061/2010/536538] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
28 Lessig S, Ubhi K, Galasko D, Adame A, Pham E, Remidios K, Chang M, Hansen LA, Masliah E. Reduced hypocretin (orexin) levels in dementia with Lewy bodies. Neuroreport 2010;21:756-60. [PMID: 20531237 DOI: 10.1097/WNR.0b013e32833bfb7c] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
29 Haq IZ, Naidu Y, Reddy P, Chaudhuri KR. Narcolepsy in Parkinson's disease. Expert Rev Neurother 2010;10:879-84. [PMID: 20518604 DOI: 10.1586/ern.10.56] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
30 Mitra T, Chaudhuri KR. Sleep dysfunction and role of dysautonomia in Parkinson's disease. Parkinsonism Relat Disord 2009;15 Suppl 3:S93-5. [PMID: 20083018 DOI: 10.1016/S1353-8020(09)70790-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]